公开(公告)号：US07022725B2

公开(公告)日：2006-04-04

申请号：US10416658

申请日：2001-11-16

申请人： Yu Momose ,  Tsuyoshi Maekawa ,  Tomoko Asakawa ,  Nozomu Sakai

发明人： Yu Momose ,  Tsuyoshi Maekawa ,  Tomoko Asakawa ,  Nozomu Sakai

IPC分类号： A61K31/42 ,  C07F261/02 ,  A61P3/00

CPC分类号： C07D231/12 ,  A61K31/42 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/675 ,  C07D233/56 ,  C07D249/08 ,  C07D261/08 ,  C07D261/12 ,  C07D261/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07F9/653 ,  C07F9/657181

摘要： A compound represented by the formula (I) wherein one of R1 and R2 is a hydrogen atom or a substituent and the other is an optionally substituted cyclic group; W is a bond or a divalent aliphatic hydrocarbon group; Y is a group of the formula: —OR3 (wherein R3 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group) or an optionally esterified or amidated carboxyl group, or a salt thereof or a prodrug thereof has a superior insulin secretion promoting action and a hypoglycemic action and shows low toxicity. Therefore, the compound is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of diabetes and diabetic complications, and the like.

摘要翻译： 由式（I）表示的化合物，其中R 1和R 2中的一个是氢原子或取代基，另一个是任选取代的环状基团; W是键或二价脂族烃基; Y是下式的基团：-OR 3（其中R 3是氢原子，任选取代的烃基，任选取代的杂环基或任选取代的酰基 基团）或任选酯化或酰胺化的羧基或其盐或其前药具有优异的胰岛素分泌促进作用和降血糖作用，并且显示低毒性。 因此，该化合物可用作药剂，特别是作为预防或治疗糖尿病和糖尿病并发症的药剂等。

公开(公告)号：US20060004069A1

公开(公告)日：2006-01-05

申请号：US10532667

申请日：2003-10-30

申请人： Yu Momose ,  Nozomu Sakai ,  Tsuyoshi Maekawa ,  Masatoshi Hazama ,  Toru Kawamura ,  Misayo Sera

发明人： Yu Momose ,  Nozomu Sakai ,  Tsuyoshi Maekawa ,  Masatoshi Hazama ,  Toru Kawamura ,  Misayo Sera

IPC分类号： A61K31/4196 ,  A61K31/4164 ,  A61K31/4152 ,  C07D43/02

CPC分类号： C07D231/12 ,  A61K31/402 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4174 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/66 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07F9/4056 ,  C07F9/5537 ,  C07F9/65031 ,  C07F9/6506 ,  C07F9/6518 ,  C07F9/653 ,  C07F9/65395 ,  C07F9/65586 ,  C07F9/657181

摘要： The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula: wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s); B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a divalent acyclic hydrocarbon group; Z is —O—, —S—, —NR2—, —CONR2— or —NR2CO— (R2 is a hydrogen atom or an optionally substituted alkyl group); Y is a bond or a divalent acyclic hydrocarbon group; R1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be —O—, or a salt thereof.

摘要翻译： 本发明提供了用于预防或治疗具有优异作用和低毒性的神经病的药剂。 该试剂包括由下式表示的化合物：其中环A是含有2个或更多个氮原子的5元芳族杂环，其可进一步具有取代基; B是任选取代的烃基或任选取代的杂环基; X是二价无环烃基; Z是-O - ， - S - ， - NR 2 - ， - CONR 2 - 或-NR 2 CO-（R SUB > 2 是氢原子或任选取代的烷基）; Y是键或二价无环烃基; R 1是任选取代的环状基团，任选取代的氨基或任选取代的酰基，条件是当由环A表示的5元芳族杂环是咪唑时，则Z不应该是 - O-或其盐。

公开(公告)号：US20110294832A1

公开(公告)日：2011-12-01

申请号：US13205967

申请日：2011-08-09

申请人： Tsuyoshi Maekawa ,  Hideyuki Igawa

发明人： Tsuyoshi Maekawa ,  Hideyuki Igawa

IPC分类号： A61K31/519 ,  A61P13/00 ,  A61P3/10 ,  C07D487/04 ,  A61P9/10

CPC分类号： C07D487/04 ,  A61K31/519

摘要： Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.

公开(公告)号：US20100197683A1

公开(公告)日：2010-08-05

申请号：US12696147

申请日：2010-01-29

申请人： Tsuyoshi Maekawa ,  Hideyuki Igawa

发明人： Tsuyoshi Maekawa ,  Hideyuki Igawa

IPC分类号： A61K31/5377 ,  C07D487/04 ,  A61K31/519 ,  C07D413/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/00 ,  A61P3/10 ,  A61P1/16 ,  A61P27/02

CPC分类号： C07D487/04 ,  A61K31/519

摘要： Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.

摘要翻译： 提供了由下式表示的新化合物，其中每个符号如说明书中所定义，或其盐，其具有血管紧张素II受体拮抗活性和过氧化物酶体增殖物激活受体γ激动活性，并且可用作试剂 用于预防或治疗诸如高血压等循环系统疾病和/或代谢疾病如糖尿病等。

公开(公告)号：US20060048883A1

公开(公告)日：2006-03-09

申请号：US10544106

申请日：2004-03-05

申请人： Tsuyoshi Maekawa ,  Heikichi Nakanome ,  Ken Takahashi

发明人： Tsuyoshi Maekawa ,  Heikichi Nakanome ,  Ken Takahashi

IPC分类号： B29D30/00

CPC分类号： B29D30/36 ,  B29D30/0645 ,  B29D2030/0647

摘要： A method of producing a radial tire for a construction vehicle, the method enabling a vast reduction in facility costs. A first green tire is formed in a first step molding machine and then removed from it. After that, a vulcanizer bladder unit is installed on the tire. The tire is inflated by the vulcanizer bladder unit and then again placed in the first step molding machine with the vulcanizer bladder unit installed. After that, on the first step molding machine, belts and tread rubber are adhered to the outer periphery of the tire to form a completed green tire. Then the completed green tire, with the vulcanizer bladder unit, is assembled in a vulcanizing mold for vulcanization.

摘要翻译： 一种生产用于建筑车辆的子午线轮胎的方法，该方法能够大大降低设备成本。 第一生胎在第一步成型机中形成，然后从其中取出。 之后，在轮胎上安装硫化器囊单元。 轮胎由硫化器囊单元充气，然后再次放置在第一步成型机中，并安装硫化器囊。 之后，在第一阶段成型机中，皮带和胎面橡胶粘附在轮胎的外周上，形成完毕的生胎。 然后将完成的带有硫化胶囊单元的生胎组装在用于硫化的硫化模具中。

公开(公告)号：US06404652B1

公开(公告)日：2002-06-11

申请号：US09436209

申请日：1999-11-08

申请人： Yasuhiro Takebayashi ,  Kazushige Matsuoka ,  Taisuke Ueda ,  Ryo Sugihara ,  Hirofumi Iwanaga ,  Tsuyoshi Maekawa

发明人： Yasuhiro Takebayashi ,  Kazushige Matsuoka ,  Taisuke Ueda ,  Ryo Sugihara ,  Hirofumi Iwanaga ,  Tsuyoshi Maekawa

IPC分类号： H02B101

CPC分类号： H01R9/2408 ,  H01H50/047 ,  H01H50/14

摘要： A relay terminal includes a plurality of relays, a connector for entering control signals to control the relays and outputting contact inputs from their relay contacts, and a terminal block corresponding to the input and output signals of the relays, which are held as a single unit. The holding construction of the plurality of relays and the terminal block employs a two step overlapping holding construction in which the relays are held in an upper step and the terminal block is held in a lower step, resulting in a reduction in the width of the relay terminal and an increase in a package density when the relay terminal is mounted on a vertical installation wall within a control panel.

摘要翻译： 继电器端子包括多个继电器，用于输入控制信号以控制继电器并从其继电器触点输出触点输入的连接器，以及与继电器的输入和输出信号相对应的端子块，其被保持为单个单元 。 多个继电器和端子排的保持结构采用两步重叠保持结构，其中继电器保持在上部阶段，并且端子块保持在较低的台阶，导致继电器的宽度减小 并且当中继端子安装在控制面板内的垂直安装壁上时，封装密度增加。

公开(公告)号：US08283353B2

公开(公告)日：2012-10-09

申请号：US12696147

申请日：2010-01-29

申请人： Tsuyoshi Maekawa ,  Hideyuki Igawa

发明人： Tsuyoshi Maekawa ,  Hideyuki Igawa

IPC分类号： A01N43/90 ,  A61K31/519 ,  C07D487/00

CPC分类号： C07D487/04 ,  A61K31/519

摘要： Provided is a novel compound represented by the following formula Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.

摘要翻译： 提供了由下式表示的新化合物，其中每个符号如说明书中所定义，或其盐，其具有血管紧张素II受体拮抗活性和过氧化物酶体增殖物激活受体γ激动活性，并且可用作试剂 用于预防或治疗诸如高血压等循环系统疾病和/或代谢疾病如糖尿病等。

公开(公告)号：US07998968B2

公开(公告)日：2011-08-16

申请号：US12625622

申请日：2009-11-25

申请人： Takanobu Kuroita ,  Hiroki Sakamoto ,  Hideyuki Igawa ,  Minoru Sasaki ,  Kouhei Asano ,  Tsuyoshi Maekawa ,  Koji Fuji

发明人： Takanobu Kuroita ,  Hiroki Sakamoto ,  Hideyuki Igawa ,  Minoru Sasaki ,  Kouhei Asano ,  Tsuyoshi Maekawa ,  Koji Fuji

IPC分类号： A61K31/505

CPC分类号： C07D413/10 ,  C07D413/14 ,  C07D417/14

摘要： A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. For example, the compound may be substituted pyrimidines and pharmaceutical compositions of the formula (I) where X=—CR3; X1=—CR2 or —NR2; and X2=—CR5 or —NR5. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.

摘要翻译： 由式（I）表示的化合物：其中R 1是氧代基，或= N-R等; 由下式表示的基团是由下式表示的基团：R 2是由下式表示的基团：R 3和R 4各自为H或C 1 -C 6烷基，C 3 -C 6环烷基，C 1 -C 6烷氧基，C 1 -C 6 烷基氨基，二（C 1 -C 6）烷基氨基或C 1 -C 6烷硫基，其各自任选被取代; 和R 5为H或C 1 -C 6烷基，C 2 -C 6烯基，环状基团，各自为任选取代的-CO-R 8或-O-R 8'或其盐。 例如，化合物可以是取代的嘧啶和式（I）的药物组合物，其中X = -CR 3; X1 = -CR2或-NR2; X2 = -CR5或-NR5。 本发明的化合物可用作预防或治疗心血管疾病，代谢疾病和/或中枢神经系统疾病的药物。

公开(公告)号：US20110118583A1

公开(公告)日：2011-05-19

申请号：US12736720

申请日：2008-05-07

申请人： Makoto Yuasa ,  Tsuyoshi Maekawa ,  Motoki Fujita ,  Shigeru Kido

发明人： Makoto Yuasa ,  Tsuyoshi Maekawa ,  Motoki Fujita ,  Shigeru Kido

IPC分类号： A61B5/04

CPC分类号： A61B5/14503 ,  A61B5/01 ,  A61B5/02152 ,  A61B5/14546 ,  A61B5/1473 ,  A61B5/4076 ,  A61B5/412 ,  A61B5/6852 ,  A61M5/1723 ,  A61M2005/1726 ,  A61M2210/0693

摘要： The device for diagnosing tissue injury of the invention has a catheter insertable into the body and a radical sensor provided in the catheter, and is characterized in that the radical sensor has a sensor electrode capable of measuring superoxide anion radicals provided at a tip end of the catheter, a lead wire connector for a sensor provided at a basal portion of the catheter, and a lead wire for a sensor for connecting the sensor electrode portion to the lead wire connector for a sensor. With the device, in vivo free radicals typified by superoxide anions in systemic organ or tissue injury caused by cerebral ischemia reperfusion injury, severe infection or sepsis can be promptly and quantitatively monitored, and whether the in vivo tissue conditions are good or not can be accurately diagnosed.

摘要翻译： 用于诊断本发明的组织损伤的装置具有可插入体内的导管和设置在导管中的根部传感器，其特征在于，该自由基传感器具有能够测量超氧阴离子自由基的传感器电极， 导管，用于设置在导管的基部的传感器的引线连接器，以及用于传感器的引线，用于将传感器电极部分连接到用于传感器的引线连接器。 使用该装置，可以迅速和定量地监测体内自由基以及由脑缺血再灌注损伤引起的系统性器官或组织损伤中的超氧阴离子代谢，可以准确地监测体内组织条件是否良好 诊断出

公开(公告)号：US20110065205A1

公开(公告)日：2011-03-17

申请号：US12532245

申请日：2008-03-27

申请人： Tsuyoshi Maekawa ,  Tomonori Izumi ,  Yasutaka Oda ,  Yuki Akiyoshi

发明人： Tsuyoshi Maekawa ,  Tomonori Izumi ,  Yasutaka Oda ,  Yuki Akiyoshi

IPC分类号： G01N33/566 ,  C07K16/18 ,  C07K16/06

CPC分类号： C07K16/18 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/52

摘要： The present invention has its main object of providing a method for determining prognosis scientifically by searching an early marker for predicting neurological prognosis in order to grasp the disease state of a patient with an acute central nervous system disorder in the early stage and enabling an appropriate treatment to be performed. The method for determining the prognosis is provided in which the expression level of SH3BGRL3 in the biological fluid of the patient within 48 hours after resuscitation from cardiopulmonary arrest is measured, and the prognosis of the disorder classified into a good prognosis group and a poor prognosis group depending on the expression level or the presence or absence of the expression based on the Glasgow Outcome Scale (GOS) is predicted.

摘要翻译： 本发明的主要目的是提供一种通过搜索用于预测神经预后的早期标记物来科学地确定预后的方法，以便在早期掌握患有急性中枢神经系统疾病的患者的疾病状态并且能够进行适当的治疗 被执行。 提供了确定预后的方法，其中测量了从心肺停止复苏后48小时内患者生物液体中SH3BGRL3的表达水平，并将该疾病的预后分类为良好的预后组和不良预后组 取决于表达水平或基于格拉斯哥结果量表（GOS）的表达的存在或不存在。